Aytu BioScience, Inc. (AYTU) financial statements (2021 and earlier)

Company profile

Business Address 373 INVERNESS PARKWAY
ENGLEWOOD, CO 80112
State of Incorp. DE
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6248117197
Cash and cash equivalents6248117187
Short-term investments     1 
Restricted cash and investments00000  
Receivables7521100
Inventory, net of allowances, customer advances and progress billings71011110
Inventory71011110
Prepaid expense      0
Other current assets116     
Other undisclosed current assets6610000
Total current assets:93751593108
Noncurrent Assets
Operating lease, right-of-use asset01
Property, plant and equipment0000100
Intangible assets, net (including goodwill)744900121
Goodwill2828  000
Intangible assets, net (excluding goodwill)462100121
Deposits noncurrent assets0000000
Other noncurrent assets 171911911 
Other undisclosed noncurrent assets(0)11  119
Total noncurrent assets:74781912121410
TOTAL ASSETS:1671533521152418
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:192032341
Accounts payable712222  
Accrued liabilities981010 
Employee-related liabilities3      
Taxes payable 0     
Other undisclosed accounts payable and accrued liabilities     41
Deferred revenue00
Debt21     
Deferred rent credit   0
Due to related parties     5 
Business combination, contingent consideration, liability41110  
Deferred revenue and credits   0
Other liabilities 1     
Other undisclosed current liabilities1611010
Total current liabilities:2628534101
Noncurrent Liabilities
Long-term debt and lease obligation1012     
Long-term debt, excluding current maturities1011     
Operating lease, liability01
Liabilities, other than long-term debt1318224741
Deferred revenue and credits 000
Deferred tax liabilities, net    0
Other liabilities05     
Business combination, contingent consideration, liability1313224741
Derivative instruments and hedges, liabilities 000 0 
Other undisclosed noncurrent liabilities5      
Total noncurrent liabilities:2830224741
Total liabilities:545828811143
Stockholders' equity
Stockholders' equity attributable to parent1139571341016
Preferred stock  0    
Common stock0000000
Additional paid in capital24721511393735739
Accumulated deficit(134)(120)(106)(79)(69)(47)(18)
Receivable from shareholders or affiliates for issuance of capital stock      (5)
Total stockholders' equity:1139571341016
TOTAL LIABILITIES AND EQUITY:1671533521152418

Income statement (P&L) ($ in millions)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Revenues522874330
Revenue, net  10
Cost of revenue(16)(8)(2)(2)(1)(1)(0)
Gross profit:352052220
Operating expenses(65)(49)(24)(23)(23)(24)(8)
Other undisclosed operating income (loss)982211(0)
Operating loss:(21)(21)(17)(20)(20)(22)(8)
Nonoperating income (expense)(2)8(10)10(2)(6) 
Other nonoperating income  06   
Interest and debt expense(0)(0)(1)(1)(3)(5) 
Loss from continuing operations before equity method investments, income taxes:(23)(14)(28)(11)(25)(34)(8)
Other undisclosed income (loss) from continuing operations before income taxes     5(0)
Loss from continuing operations before income taxes:(23)(14)(28)(11)(25)(28)(8)
Income tax benefit      0
Loss before gain (loss) on sale of properties:(23)(14)(28)(11)(25)(28)(8)
Other undisclosed net loss(0)      
Net loss:(23)(14)(28)(11)(25)(28)(8)
Other undisclosed net income attributable to parent10113  
Net loss available to common stockholders, diluted:(22)(14)(27)(10)(23)(28)(8)

Comprehensive Income ($ in millions)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Net loss:(23)(14)(28)(11)(25)(28)(8)
Comprehensive loss, net of tax, attributable to parent:(23)(14)(28)(11)(25)(28)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: